[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2385240A1 - Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. - Google Patents

Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. Download PDF

Info

Publication number
ES2385240A1
ES2385240A1 ES201031146A ES201031146A ES2385240A1 ES 2385240 A1 ES2385240 A1 ES 2385240A1 ES 201031146 A ES201031146 A ES 201031146A ES 201031146 A ES201031146 A ES 201031146A ES 2385240 A1 ES2385240 A1 ES 2385240A1
Authority
ES
Spain
Prior art keywords
activity
report
fatty acids
polyunsaturated fatty
documents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201031146A
Other languages
English (en)
Other versions
ES2385240B1 (es
Inventor
Antonio Parente Dueña
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
Original Assignee
GP Pharm SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GP Pharm SA filed Critical GP Pharm SA
Priority to ES201031146A priority Critical patent/ES2385240B1/es
Priority to PCT/EP2011/003737 priority patent/WO2012013331A2/en
Publication of ES2385240A1 publication Critical patent/ES2385240A1/es
Application granted granted Critical
Publication of ES2385240B1 publication Critical patent/ES2385240B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica en forma de cápsula que contiene ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos para el tratamiento y/o prevención de enfermedades de la próstata y/o transtornos hiperandrogénicos.

Claims (2)

  1. REIVINDICACIONES
    OFICINA�ES�AAOL� DE��ATENTES�R�MARCA�
    NAo�soaicitud:2
    ES�AA�
    22Fecha�de�presentaci6n�de�aa�soaicitud:��2� A2
    2 Fecha�de�prioridad:
    INFORME�SOBRE�EL�ESTADO�DE�LA�TECNICA
    Int. Cl. Ver�Hoaa�Adicionaa�
    DOCUMENTOS�RELEVANTES�
    Categoria
    @ Documentos citados Reivindicaciones afectadas
    X A A A E����52 8��IBSA�INSTITUT�BIOCHIMIQUE�SAAA2��5� ��A2� pgrrafos� � �]�����;�eaempao� LIANG2�TECHMING�et�aaA;�"Inhibition�of�steroid�5�aapha�reductase�by�specific�aaiphatic�unsaturated fatty�acids";��Biochem�EA2�2852�pgginas55��5�22��992;�ISSN2 �2� WO���285 ���INSTITUTO�HELMA�ROST2�SALA;�RUFFLES2�GA.A2�2�A��A2 DEUTSCH2 ERIC et aaA; Environmentaa2 genetic and moaecuaar features of prostate cancer; The Lancet�Oncoaogy2�voaumen�52�pgginas ��2�mayo2 A �2� 8 2 �22 2 2 2 ��2�
    Categoria�de�aos�documentos�citados X:�de�particuaar�reaevanci� R:�de�particuaar�reaevancia�combinado�con�otro�s�de�a� �����misma�categori� A:�refaeaa�ea�estado�de�aa�tdcnica� O:�referido�a�divuagaci6n�no�escrita �:�pubaicado�entre�aa�fecha�de�prioridad�yaa�de�presentaci6n ����de�aa�soaicitu� E:�documento�anterior2�pero�pubaicado�despuds�de�aa�fech� �����de�presentaci6n�de�aa�soaicitud
    El presente informe ha sido realizado � para�todas�aas�reivindicaciones � para�aas�reivindicaciones�no:�
    Fecha de realizaci6n del informe ��A��A2 2 Examinador NA�Vera�Gutierrez� Pagina �
    INFORME DEL�ESTADO �DE�LA�TECNICA
    No�de�soaicitud: 2
    CLASIFICACION�OBEETO �DE�LA�SOLICITUD
    A61K9148 ��2���A2 A61K311201 ��2���A2 A61K311202 ��2���A2
    Documentaci6n�minima�buscada��sistema�de�caasificaci6n�seguido de�aos simboaos de�caasificaci6n2
    A.
    Bases de datos eaectr6nicas consuatadas durante aa busqueda �nombre de aa base de datos y2 si es posibae2 tdrminos de busqueda�utiaizados2 INVENES2�E�ODOC2�BIOSIS2 �MEDLINE2�EMBASE2�N�L2�X�ES
    Informe�dea �Estado�de�aa�Tdcnica ggina�2�
    OPINION ESCRITA
    No�de�soaicitud:2
    Fecha�de�Reaaizaci6n�de�aa�Opini6n�Escrita: ��A��A2 2
    Declaraci6n
    Novedad (Art. .1 LP 11/198 ) Reivindicaciones 22 822 �2�222 2 SI Reivindicaciones 2 529 ���28 �2�22 2 NO
    Actividad inventiva (Art. 8.1 LP11/198 ) Reivindicaciones 222 ���2�2222 SI Reivindicaciones 2 ��28 2�22 2 NO
    Se�considera�que�aa�soaicitud cumpae�con�ea requisito�de�apaicaci6n�industriaaA�Este�requisito�fue�evaauado�durante�aa�fase�de examen�formaa y tdcnico�de�aa soaicitud��Articuao �A2�Ley ��98 �2A
    Base de la Opini6n.-
    La�presente�opini6n�se ha�reaaizado�sobre�aa base�de�aa�soaicitud�de�patente�taa y �como�se �pubaicaA
    Informe�dea �Estado�de�aa�Tdcnica ggina�
    OPINION ESCRITA
    No�de�soaicitud:2
    1. Documentos considerados.-
    A�continuaci6nse reaacionan�aos�documentos pertenecientes aa�estado de aa�tdcnica�tomados en�consideraci6n para�aa reaaizaci6n�de�esta�opini6nA
    Documento
    Numero Publicaci6n o Identificaci6n Fecha Publicaci6n
    D
    E����52��8��IBSA�INSTITUT�BIOCHIMIQUE�SAAA2 �5A��A2
    D2
    LIANG2 TECHMING�et�aaA;�"Inhibition�of�steroid�5�aapha�reductase by �specific aaiphatic unsaturated�fatty �acids" Biochem �EA2 �2852 pgginas 55 5 �22��992;�ISSN2 2A �992
  2. 2. Declaraci6n motivada segun los articulos 29. y 29.7 del Reglamento de ejecuci6n de la Ley 11/198 , de 20 de marzo, de Patentes sobre la novedad y la actividad inventiva; citas y explicaciones en apoyo de esta declaraci6n
    La invenci6n se refiere a una cgpsuaa farmacdutica que comprende una suspensi6n de microcgpsuaas poaimdricas que comprenden�aa �menos un�poaimero y aa�menos un�principio�activo�farmacdutico para ea�tratamiento y�o�prevenci6n�de�aas enfermedades de�aa pr6stata y ��o�trastornos hiperandrogdnicos2 �estando�dichas microcgpsuaas suspendidas en un�aceite�que contiene�gcidos grasos poaiinsaturadosA
    Ea documento D divuaga composiciones farmacduticas en forma de cgpsuaas de geaatina baanda que incauyen microcgpsuaas de�gcido�acetia saaiciaico�en�etiaceauaosa�suspendidas en�gcidos grasos poaiinsaturados de�aa�serie�omega
    �eaempao��2A
    Se�considera�que�aa�invenci6n recogida�en�aas reivindicaciones 2 529 �2��8�2�22 2 �no�es nueva��ArticuaoA ��LA �A2
    Respecto a aas reivindicaciones �82 reaativas aa empaeo de gcidos grasos poaiinsaturados pertenecientes a aa serie omega 2 ea�documento D 2 divuaga�un estudio�en ea �que se�ensayan distintos gcidos grasos poaiinsaturados de aas series omega y omega���como inhibidores de aa 5 �aafa�reductasaA�Se �considera�que �estas reivindicaciones no �poseen �actividad �inventiva2 dado�que�un�experto�en�aa�materiaintentaria�combinar�ea�uso�de�aos�gcidos�grasos�de�aa�serie�omega a�aa�invenci6n recogida�enD ��con�una�expectativa�razonabae�de�dxitoA
    Ninguno de aos �documentos citados divuagan cgpsuaas farmacduticas �con�aas caracteristicas detaaaadas �en aa �reivindicaci6n de aa soaicitud en aas que ea principio activo pertenezca aa grupo formado por baoqueadores aafa�adrendrgicos2 inhibidores de aa�5�aafa�reductasa2�mepartricina2�andarina2�antiandr6genos2 inhibidores de aa�sintesis de�andr6genos adrenaaes2 �angaogos de aa vitamina D y angaogos de LHRHA or eaao2 se considera que aas reivindicaciones 22 2 2 222 2 son nuevas e impaican actividad�inventiva��Articuao�8A ��LA �A2A
    Informe�dea �Estado�de�aa�Tdcnica ggina�
ES201031146A 2010-07-26 2010-07-26 Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. Expired - Fee Related ES2385240B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201031146A ES2385240B1 (es) 2010-07-26 2010-07-26 Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
PCT/EP2011/003737 WO2012013331A2 (en) 2010-07-26 2011-07-26 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201031146A ES2385240B1 (es) 2010-07-26 2010-07-26 Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.

Publications (2)

Publication Number Publication Date
ES2385240A1 true ES2385240A1 (es) 2012-07-20
ES2385240B1 ES2385240B1 (es) 2013-09-23

Family

ID=44630202

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201031146A Expired - Fee Related ES2385240B1 (es) 2010-07-26 2010-07-26 Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.

Country Status (2)

Country Link
ES (1) ES2385240B1 (es)
WO (1) WO2012013331A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
MX2014011139A (es) * 2012-04-13 2015-07-17 Banner Life Sciences Llc Cápsulas elásticas blandas que contienen comprimidos y rellenos líquidos o semisólidos y métodos para su fabricacion.
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
SG11201407679PA (en) * 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
KR20160065968A (ko) * 2013-10-08 2016-06-09 훼링 비.브이. Pgss에 의해 제조되는 gnrh를 포함하는 미립자
CN103788366B (zh) * 2014-01-22 2015-10-28 沈阳药科大学 单甲氧基聚乙二醇-二硫-二维生素e琥珀酸酯及其制备和应用
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
AU2017272888B2 (en) * 2016-06-03 2020-04-30 Avexxin As Combination therapy comprising a polyunsaturated ketone and a secosteroid
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
SG11202008715WA (en) 2018-03-15 2020-10-29 R P Scherer Technologies Llc Enteric softgel capsules
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113750032B (zh) * 2020-06-01 2024-07-16 成都海博为药业有限公司 一种口服的阿比特龙药物组合物及其制备方法及用途
CN111905106A (zh) * 2020-09-14 2020-11-10 陕西科技大学 一种缓释型海藻酸钠/壳聚糖/玉米醇溶蛋白复合材料及其制备方法
IT202200011114A1 (it) * 2022-05-26 2023-11-26 Recordati Ind Chimica E Farmaceutica S P A “uso dell’associazione tadalafil e vitamina d3 per la preparazione di un prodotto per il trattamento orale della ipertrofia prostatica benigna e relativi metodi produttivi”

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028566A1 (en) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5312473B1 (es) 1971-05-24 1978-05-01
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5035896A (en) 1988-06-15 1991-07-30 Warner-Lambert Company Water insoluble drugs coated by coacervated fish gelatin
AU5157590A (en) * 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
JPH0977663A (ja) * 1995-07-07 1997-03-25 Nippon Kayaku Co Ltd フルタミド組成物
US5952003A (en) 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
GB9717428D0 (en) 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
AU2870899A (en) 1998-02-26 1999-09-15 Abbott Laboratories Oral formulation for hydrophilic drugs
AU5486899A (en) 1998-08-13 2000-03-06 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6656969B2 (en) 2001-09-20 2003-12-02 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
ES2496102T3 (es) * 2003-03-28 2014-09-18 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
WO2006099121A2 (en) 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
CN1765363A (zh) * 2005-10-21 2006-05-03 宛六一 萘哌地尔软胶囊及其制备方法
EP2050436A1 (en) 2007-12-21 2009-04-22 Siegfried Generics International AG Pharmaceutical composition containing dutasteride
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363964B1 (es) * 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028566A1 (en) * 1999-10-19 2001-04-26 Instituto Helmaprost, S.L. Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
EP1352648A1 (en) * 2002-04-08 2003-10-15 Ibsa Institut Biochimique S.A. Pharmaceutical compositions of acetylsalicylic acid and omega-3 oils

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEUTSCH, ERIC et al.; Environmental, genetic and molecular features of prostate cancer; The Lancet Oncology, volumen 5, páginas 303-313, mayo 2004. *
LIANG, TECHMING et al.; "Inhibition of steroid 5-alpha-reductase by specific aliphatic unsaturated fatty acids" Biochem J., 285, páginas 557-562, 1992; ISSN 0264-6021. *

Also Published As

Publication number Publication date
WO2012013331A2 (en) 2012-02-02
WO2012013331A3 (en) 2012-06-28
ES2385240B1 (es) 2013-09-23

Similar Documents

Publication Publication Date Title
ES2385240A1 (es) Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
Sodero et al. Cellular stress from excitatory neurotransmission contributes to cholesterol loss in hippocampal neurons aging in vitro
Zouk et al. Characterization of impulsivity in suicide completers: clinical, behavioral and psychosocial dimensions
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
AR065135A1 (es) Compuestos triciclicos, composicion que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides.
BR112015005862A2 (pt) derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase
BR112018075433A2 (pt) derivados de piperidinila, processo para sua preparação e composições farmacêuticas contendo-os
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
DOP2013000194A (es) Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos
CO6351778A2 (es) Acidos naftilaceticos
PE20081684A1 (es) Microcapsulas vegetarianas
CR20120556A (es) Composiciones farmacéuticas y métodos para su elaboración
UY32423A (es) Derivados de azaspiranil-alquilcarbamatos de 5 eslabones, su preparacion y su aplicacion en terapeutica
Huang et al. Zinc oxide nanoparticle causes toxicity to the development of mouse oocyte and early embryo
Zheng et al. Drug-induced pancreatitis: an update
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015030431A2 (pt) formulação de liberação modificada
DOP2009000130A (es) Sal de potasio cristalina de analogos de lipoxina a4
BR112012019307A2 (pt) processo para produzir composições de etanol anidras
Kim et al. Decursin prevents cisplatin-induced apoptosis via the enhancement of antioxidant enzymes in human renal epithelial cells
Canseco-Alba et al. Cannabis: drug of abuse and therapeutic agent, two sides of the same coin
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
Wang et al. Cytoprotection of human endothelial cells against oxidative stress by 1-[2-cyano-3, 12-dioxooleana-1, 9 (11)-dien-28-oyl] imidazole (CDDO-Im): application of systems biology to understand the mechanism of action
UY27612A1 (es) Sales estables del ácido o-acetilsalicílico con aminoácidos básicos l l
BRPI0510136A (pt) prodrogas esteróides com efeito androgênico

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2385240

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130923

FD2A Announcement of lapse in spain

Effective date: 20210915